Private equity firm
The New York-based firm is holding talks with advisers about a listing in the first half of 2022 that could value the Houston-based chemical maker at about $5 billion, said the people, who asked not to be identified because they weren’t authorized to speak publicly. A final decision hasn’t been made and SK could elect to keep the business, the people said.
A representative for SK declined to comment. A spokesperson for Ascend didn’t ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.